8-K: Brainstorm Cell Therapeutics Faces Potential Delisting from Nasdaq Due to Minimum Bid Price Non-Compliance

Brainstorm Cell Therapeutics is appealing a Nasdaq decision to delist its stock after failing to meet the minimum bid price requirement.

Summary

• Brainstorm Cell Therapeutics received a notice from Nasdaq on November 1, 2023, stating they did not meet the minimum bid price of $1.00 per share.
• The company was given until April 29, 2024, to regain compliance.
• On May 1, 2024, Nasdaq confirmed that Brainstorm had not regained compliance and would be delisted.
• Brainstorm has requested a hearing with the Nasdaq Hearings Panel to appeal the delisting decision.
• The hearing request has temporarily stayed the suspension of the company's securities.
• Brainstorm intends to participate in an expedited review process with the Panel.
• The company's stock will continue to trade on Nasdaq under the symbol BCLI pending the outcome of the hearing process.
• There is no guarantee that the Panel will grant an exception or that Brainstorm will be able to regain compliance.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (potential delisting) and uncertainty about the future, leading to a low sentiment score.

Positives

• The company has successfully requested a hearing to appeal the delisting decision.
• The hearing request has temporarily stayed the suspension of the company's securities.
• Brainstorm is participating in an expedited review process which may lead to a quicker resolution.
• The company's stock will continue to trade on Nasdaq while the appeal process is ongoing.

Negatives

• Brainstorm failed to meet the minimum bid price requirement of $1.00 per share.
• The company received a delisting notice from Nasdaq.
• There is no guarantee that the company will be granted an exception to regain compliance.
• The company faces the risk of being delisted from Nasdaq.

Risks

• There is a risk that the Nasdaq Hearings Panel will not grant an exception to the delisting.
• The company may not be able to regain compliance with the minimum bid price requirement.
• Delisting from Nasdaq could negatively impact the company's stock price and investor confidence.
• The company's plan to regain compliance may not be accepted by the Panel.

Future Outlook

The company intends to present a plan to regain compliance with the Minimum Bid Price Requirement at the Panel hearing, but there is no assurance that the Panel will grant an exception or that the company will be able to regain compliance.

Management Comments

• The company intends to participate in the expedited review process provided by the Panel.
• The company intends to present a plan to regain compliance with the Minimum Bid Price Requirement at the Panel hearing.

Industry Context

This situation is not uncommon for companies with struggling stock prices, and many companies have faced similar delisting notices from Nasdaq. The outcome of Brainstorm's appeal will be closely watched by other companies in similar situations.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face challenges in maintaining their stock price above the minimum bid price requirement.
• Companies like Athersys and Ocugen have also faced similar delisting notices in the past, highlighting the volatility and risk associated with the biotech sector.
• The success of Brainstorm's appeal will depend on the strength of their plan to regain compliance and the Panel's assessment of their future prospects.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation and ability to raise capital may be negatively impacted.

Next Steps

• Brainstorm will participate in an expedited review process with the Nasdaq Hearings Panel.
• The company will present a plan to regain compliance with the minimum bid price requirement at the Panel hearing.
• The Panel will issue a decision regarding the company's appeal.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, hearing, appeal, BCLI, Brainstorm Cell Therapeutics